Atlas' 2022 fund, which raised the same amount and supported the launch of 16 companies, ended up backing four companies or programmes that went on to be acquired by big pharma groups (Nimbus ...

An array of pharmaceutical pills with the ... fatty liver disease and chronic kidney disease. We believe the premium valuation is supported by this outsized growth profile.” ...

Repirinast is the Company’s lead candidate for the treatment of CKD based on data showing it reduced fibrosis by 51% with statistical significance and showed an additive benefit to telmisartan in a ...

The FDA has issued a CRL to Lexicon regarding the NDA for Zynquista (sotagliflozin) as an adjunct to insulin therapy for T1D and CKD.

While observational studies indicated a positive association between smoking status and the risk of CKD, the Mendelian randomization analysis revealed no evidence of a causal relationship.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Avadel Pharmaceuticals (AVDL – Research ...

Veeda Group has unveiled a new logo and brand identity— Veeda Lifesciences —reflecting the brand’s evolution from a ...

CKD-510 is under clinical development by Novartis and currently ... proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center. Give ...

Behind every name for a product or drug is someone writing hundreds of possible names. Lieba Golden-Koulendros made a career ...

An icon in the shape of a lightning bolt. Impact Link Big Pharma will hunt for more acquisitions in 2025 as industry giants face patent expiration for some of their best-selling drugs, according ...